Our research in response to the global pandemic

Until a vaccine is available, there is an immediate need for medicines that can prevent life-threatening complications of COVID-19.


Identifying a potential coronavirus treatment using our Knowledge Graph

1-2 February 2020

Using our AI tools and biomedical knowledge graph we identified baricitinib as a potential treatment to inhibit viral infection.

4 February 2020

Our research was published in The Lancet and we signed the Wellcome Trust pledge to share our research in response to the emerging global health crisis
Read more →

28 February 2020

We published a second paper which indicated that baricitinib reduces endocytosis and the body’s hyperinflammatory response to the virus, thus potentially reducing patient mortality.
Read more →

10 April 2020

Eli Lilly (who owns baricitinib) announces that baricitinib will enter a randomised-control trial with the US National Institute of Allergy and Infectious Diseases (NIAID).
Read more →

15 June 2020

Eli Lilly announced that they will commence an additional phase 3 clinical trial to evaluate the efficacy and safety of baricitinib to treat COVID-19.

26 June 2020

Further experimental data supporting our AI-derived hypothesis and early results from clinical testing were published in the European Molecular Biology Organization Molecular Medicine Journal. This research was conducted in partnership with Eli Lilly.
Read more →

14 September 2020

Positive data released from the NIAID’s randomised-control trial showed that baricitinib in combination with remdesivir reduces the recovery time in hospitalised patients with COVID-19, validating our AI-derived hypothesis.
Read more →

19 November 2020

The FDA granted Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients, nine months after BenevolentAI's initial hypothesis was published. This decision was based on data from the NIAID ACTT-2 trial, validating our AI-derived hypothesis.
Read more →

If you would like further information, please contact our press team.